



(51) International Patent Classification:
C07K 16/28 (2006.01) A61P 1/00 (2006.01)

(21) International Application Number:
PCT/EP2024/084141

(22) International Filing Date:
29 November 2024 (29.11.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23213466.8 30 November 2023 (30.11.2023) EP
24210868.6 05 November 2024 (05.11.2024) EP

(71) Applicant: ONCOSPEAR APS [DK/DK]; Tesdorpfvej 12, 5000 Odense C (DK).

(72) Inventors: GRAVERSEN, Niels Jonas Heilskov; c/o OncoSpear ApS, Tesdorpfvej 12, 5000 Odense C (DK). JENSEN, Maria Pauladottir; c/o OncoSpear ApS, Tesdorpfvej 12, 5000 Odense C (DK). STRAUSS, Line Moesgaard; c/o OncoSpear ApS, Tesdorpfvej 12, 5000 Odense C (DK). HØGH, Rikke Illum; c/o OncoSpear ApS, Tesdorpfvej 12, 5000 Odense C (DK). MOULIN, Morgane Jennifer; c/o OncoSpear ApS, Tesdorpfvej 12, 5000 Odense C (DK). SKYTTHE, Maria Kløjgaard; c/o On-

coSpear ApS, Tesdorpfvej 12, 5000 Odense C (DK). ET-ZERODT, Anders; c/o OncoSpear ApS, Tesdorpfvej 12, 5000 Odense C (DK).

(74) Agent: PLOUGMANN VINGTOFT A/S; Strandvejen 70, 2900 Hellerup (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANTI-CD163 ANTIBODIES WITH IMPROVED ADCC CAPABILITIES

(57) Abstract: The present disclosure relates to improved antibodies targeting CD163. In particular, the present disclosure relates to improved antibodies targeting CD163 with improved capabilities in relation to inducing Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).




Fig. 13D

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*